Gsa Capital Partners LLP Trevena Inc Transaction History

Gsa Capital Partners LLP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 09, 2022	SELL	$0.2 - $0.5 $171,396 - $428,491	-856,983 Closed	0 $0
Q1 2022 May 11, 2022	BUY	$0.41 - $0.63 $351,363 - $539,899	856,983 New	856,983 $471,000
Q4 2019 Feb 12, 2020	SELL	$0.62 - $1.06 $69,612 - $119,015	-112,279 Closed	0 $0
Q3 2019 Nov 12, 2019	BUY	$0.81 - $1.06 $90,945 - $119,015	112,279 New	112,279 $109,000
Q4 2018 Feb 12, 2019	SELL	$0.39 - $3.47 $105,396 - $937,757	-270,247 Closed	0 $0
Q3 2018 Nov 13, 2018	SELL	$1.39 - $2.25 $113,423 - $183,600	-81,600 Reduced 23.19%	270,247 $573,000
Q2 2018 Aug 09, 2018	BUY	$1.44 - $2.24 $329,616 - $512,736	228,900 Added 186.18%	351,847 $507,000
Q1 2018 May 11, 2018	SELL	$1.51 - $2.06 $40,770 - $55,620	-27,000 Reduced 18.01%	122,947 $202,000
Q4 2017 Feb 14, 2018	BUY	$1.4 - $2.6 $81,760 - $151,840	58,400 Added 63.79%	149,947 $240,000
Q3 2017 Nov 20, 2017	BUY	$2.22 - $2.79 $203,234 - $255,416	91,547	91,547 $233,000

Ticker TRVN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 173,680,992
Market Cap $294M
Description
Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV...

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Gsa Capital Partners LLP with notifications on news.